Compare Endeavour Silver Corp (EXK) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Inovio Pharmaceuticals Inc — how do they compare? Endeavour Silver Corp trades at $10.26 (market cap $3.14B), while Inovio Pharmaceuticals Inc trades at $0.82 (market cap $78.67M). The key difference: Endeavour Silver Corp is far larger — about 39.9× Inovio Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EXK | INO | |
|---|---|---|
Market Cap | $3.14B | $78.67M |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $2.87 |
52-Week Low | $5.31 | $0.66 |
Enterprise Value | $3.15B | $50.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK trades at $10.61, up 3.61% today, with a bullish technical signal from moving averages and a consensus analyst price target of $15.50. Recent Q2 2026 earnings matched estimates at $0.15 per share, while Q1 2026 beat expectations. The company reported strong production growth and secured a $25 million credit facility in August 2026, supporting operational expansion.
Outlook is positive due to rising revenue, improved profitability projected for 2026, and favorable metal prices. Risks include high P/E ratio of 52.95, volatile earnings history, and dependence on commodity markets. Institutional sentiment is bullish with 78.57% buy ratings.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
